Clinical Trial Update: Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 trial conducted by Conatus Pharmaceuticals evaluated the safety and efficacy of a caspase inhibitor (emricasan) in patients undergoing liver transplan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholestasis
• Hepatocellular Carcinoma
• Viral Hepatitis

Drugs mentioned

• Emricasan (emricasan)

Snippet

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Liver Transplantation, Hepatitis | Phase 2 | Status: COMPLETED